Holder plans sale of 2,021 Vertex shares

A holder of Vertex Pharmaceuticals (VRTX) filed a Rule 144 notice to sell 2,021 common shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/11/2026.

Rhea-AI Filing Summary

A holder of Vertex Pharmaceuticals (VRTX) filed a Rule 144 notice to sell 2,021 common shares through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 02/11/2026. The filing lists an aggregate market value of $930,529.03 and 253,718,831 shares outstanding.

The 2,021 shares derive from restricted stock vesting on 02/10/2026, received as compensation from the issuer. The filing also notes a prior sale by Mark E. Bunnage of 23 common shares on 12/29/2025 for gross proceeds of $10,649.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the VRTX Form 144 filing disclose about planned share sales?

The Form 144 notice discloses an intention to sell 2,021 Vertex common shares on NASDAQ. These shares are valued at an aggregate $930,529.03, providing investors insight into a planned secondary market transaction by an existing holder.

How many Vertex (VRTX) shares are outstanding in this Form 144?

The notice states that 253,718,831 Vertex common shares are outstanding. This figure helps investors gauge the relative size of the planned 2,021-share sale compared with the company’s total common equity base at the time of the filing.

What is the source of the 2,021 Vertex (VRTX) shares being sold?

The 2,021 shares come from restricted stock vesting on 02/10/2026. The securities were acquired from the issuer as compensation, meaning they reflect equity-based pay that has recently vested and is now eligible for sale under Rule 144.

Which broker and exchange are involved in the VRTX Form 144 sale?

The filing shows the shares will be sold through Fidelity Brokerage Services LLC and listed on the NASDAQ exchange. This indicates the transaction will occur in the public market using a mainstream brokerage platform and trading venue.

Does the VRTX Form 144 mention any recent prior sales by the same holder?

Yes. It reports a prior sale by Mark E. Bunnage of 23 Vertex common shares on 12/29/2025 for $10,649.00 in gross proceeds. This disclosure covers sales during the three months preceding the new planned transaction.

What representation does the seller make in the VRTX Rule 144 notice?

By signing, the person for whose account the securities are sold represents they do not know any undisclosed material adverse information about Vertex’s current or prospective operations, aligning with Rule 144 requirements for public resale of restricted or control securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 10:18 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002100735
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Bunnage Mark E.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2021	930529.03	253718831	02/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2026	Restricted Stock Vesting	Issuer			2021	02/10/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Mark E. Bunnage 50 Northern Avenue Boston MA 02210	Common	12/29/2025	23	10649.00

144: Remarks and Signature

Remarks
Date of Notice	02/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jennifer Ruchti, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Mark E. Bunnage
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)